The target protein of ezetimibe, NPC1-L1, known to be present in the intestine, was recently shown to be present in hepatocyte and Kupffer cells, affecting bile cholesterol reabsorption, which is expected to have a pleiotropic effect on hepatic steatosis [30, 32]. The gene discussed is NPC1L1; the disease is Hepatic steatosis.